Cologuard - EXAS Forward P/S Multiple

Symbol and logo of brand Exact Sciences Inc. (EXAS)

The foundation of Exact Sciences (EXAS) is a strong team of oncologists and bioinformaticians, which ensures the protection of Cologuard patents and strict compliance with FDA regulations. AI-driven DNA analysis robotics optimize processes, while the company's modeled P/S on the GURU.Markets time series visualizes the market valuation. Meanwhile, 6.20 is the current value of the indicator, capturing the sales forecast.

Exact Sciences Corp - EXAS Forward Price-to-Revenue Multiple (period 07/04/2022 - 04/04/2026)

Comprehensive metric breakdowns and analytics for Exact Sciences Inc. (EXAS)

- stock price and consensus target price:
Stock Quotes Exact Sciences Corporation|EXAS - Broker Consensus Forecast
- issuer market value details:
Market Capitalization Exact Sciences Inc.|EXAS - Enterprise Value
- issuer book value statistics:
Book Value per Share Exact Sciences|EXAS - Company Net Assets|Market Cap to Net Assets Ratio exactsciences.com|EXAS - Aggregate Business Assets
- issuer credit burden and liquidity indicators:
Total Debt to Equity Ratio Exact Sciences|EXAS - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Exact Sciences|EXAS - Company Total Debt Obligations|Debts to Book Capitalization Exact Sciences Inc.|EXAS - Company Long-Term Liabilities|Company Short-Term Debts Exact Sciences|Quick Ratio exactsciences.com
- financial results and valuation multiples details:
EXAS - Company Net Income|Expected Profit Exact Sciences|EXAS - Price to Earnings Multiple|Forward P/E Multiple Cologuard|EXAS - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Exact Sciences Inc.|EXAS - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Exact Sciences|EXAS - Net earnings per share for the last four quarters|Quarterly EPS earnings growth exactsciences.com|EXAS - Earnings per share growth rate in current year|Expected earnings per share growth for next year Exact Sciences
- sales and revenue data:
EXAS - Company Sales Volume|Projected Sales Volume Exact Sciences Corporation|EXAS - P/S Multiple|Price-to-Projected Revenue Ratio Exact Sciences Inc.
Comprehensive company analysis:Exact Sciences Corporation EXAS
Manufactured products of Exact Sciences

For Exact Sciences (EXAS), which seeks leadership in early cancer detection by scaling Cologuard, this indicator determines the market value of one dollar of expected sales. By analyzing the forward price-to-sales ratio, an investor assesses the market's willingness to pay a premium for the expansion of liquid biopsy. The stability of this ratio on the chart allows for the identification of asset overheating or confirms the presence of a fundamental margin of safety.

Competitors of Exact Sciences (EXAS)

Agilent - Forward Price-to-Revenue Multiple|DGX: Market Cap to Projected Revenue|Illumina Corp - Forward P/S Multiple|RVTY - Forward P/S Multiple|BIO: Forward P/S Multiple|Forward Price-to-Revenue Multiple anbio.com|Forward Price-to-Revenue Multiple SHC|QDEL (Quidel Corporation) - Price to Expected Revenue Ratio|Forward Price-to-Revenue Multiple OPK (OPKO Corp)|CDNA (CareDx Health) - Forward Price to Sales|Price-to-Projected Revenue Ratio Maravai LifeSciences MRVI|Market Cap to Expected Sales Ratio fulgentgenetics.com (FLGT)|Standard BioTools - Forward P/S Multiple|Cytek Biosciences Inc (CTKB) - Forward Price-to-Revenue Multiple|OSUR: Forward P/S Multiple|XGN - Market Cap to Expected Sales Ratio|MDXH (MDxHealth SA) - Forward P/S Multiple|Market Cap to Future Revenue Ratio luciddx.com LUCD|Price-to-Projected Revenue Ratio Prenetics Global (PRE)|imdxinc.com - Market Cap to Projected Revenue|Forward P/S Multiple TRIB (Trinity Biotech)|PRPH - Forward Price-to-Revenue Multiple|Ainos, Inc. - Forward P/S Multiple|Market Cap to Future Revenue Ratio codiagnostics.com|HeartSciences (HSCS) - Price-to-Projected Revenue Ratio|BMRA - Market Cap to Expected Sales Ratio|CDIO (Cardio Diagnostics Holdings Inc.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Onconetix Corporation ONCO|Forward Price-to-Revenue Multiple VRAX (Virax Biolabs Group)|bluejaydx.com - Market Cap to Projected Revenue|Forward P/S Multiple AWH (Aspira Women's Health Inc.)|Forward P/S Multiple Accelerate Diagnostics Inc. AXDX|CNTG - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Enzo Biochem, Inc. ENZ|fresh2.co (FRES) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple Genetic Technologies Limited|ME (23andMe) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Psychemedics Corp. PMD